Skip to content

Effect of Breakfast or Omission of Breakfast in T2D

Effect of Breakfast Omission on Postprandial Glycemia After Lunch and Dinner in T2D

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01571310
Acronym
OB-B
Enrollment
30
Registered
2012-04-05
Start date
2012-07-31
Completion date
2016-05-31
Last updated
2017-10-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

The investigators will explore the effect of omission of breakfast on postprandial hyperglycemia and insulin and intact GLP-1 response after subsequent meals in type 2 diabetic patients

Detailed description

In obesity and in type 2 diabetes eating behavior especially the lack of breakfast promote weight gain, increase hunger and carbohydrate craving. The present study is designed to address whether in T2D, a change in meal timing; specifically, by adding calories, protein and carbohydrates to the breakfast vs.the omission of breakfast will influence the postprandial elevation of glucose, insulin, intact GLP-1, glucagon and free fatty acids (FFA) after subsequent meals at lunch and dinner. The investigators expect that compared to the day with breakfast condition the day when the breakfast will be omitted the postprandial glucose , free fattly acids, and glucagon response after lunch and dinner will be significative higher while insulin and intact GLP-1 response after lunch and dinner will be reduced

Interventions

OTHEROmitted Breakfast

Experimental:The patients in Omitted Breakfast day will omit the breakfast and will continue the overnight fast until lunch. They will eat only lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00

In the Active Comparator: The patients in the Breakfast day will consume breakfast (700 kcal) at 8:00 , lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00 (YesB): The patients in YesB will eat all three mealswill consume three meals:

Sponsors

Hospital de Clinicas Caracas
CollaboratorOTHER
Tel Aviv University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
30 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

1. Type 2 diabetics for \< 10yr 2. HbA1C: 7-9 % 3. BMI: 22 to 35 kg/m2) 4. Age: ≥30 and ≤70 years of age 5. Habitually eat breakfast 6. Naïve or treated with oral antidiabetic drugs and those with anti-hypertensive and lipid-lowering medication 7. Those treated with insulin or GLP-1 analogs or having major liver, heart or kidney illnesses will be excluded. 8. Usually wake up between 06:00 and 07:00 and go to sleep between 22:00 and 24:00. 9. Not dieting and no change in body weight \>10 lb = 4.5 kg within the last 6 months 10. Stable physical activity pattern during the three months immediately preceding study initiation 11. Normal liver and kidney function 12 No metabolic disease other then diabetes 13\. Usually wakes up between 05:00 and 07:00 and goes to sleep between 22:00 and 24:00. 15\. Normal TSH and FT4 levels 16. Acceptable health based on interview, medical history, physical examination, and laboratory tests 17. Those who provide signed informed consent

Exclusion criteria

1. Type 1 diabetes 2. Pulmonary disease, psychiatric, immunological, neoplastic diseases or severe diabetic complications, such as cardiovascular disease, cerebrovascular disease, proliferative diabetic retinopathy, gastroparesis or underwent bariatric surgery. 3. Abnormal liver function tests defined as an increase by a factor of at least 2 above the upper normal limit of alanine aminotransferase and/or aspartate 4. Anemia (Hg \> 10g/dL) 5. Serum creatinine level \> 1.5 mg/dl 6. Pregnant or lactating 7. Participating in another dietary program or use of weight-loss medications 8. Documented or suspected history (within one year) of illicit drug abuse or alcoholism. 9. Use of psychotropic or anoretic medication during the month immediately prior to study onset 13.Work shifts within the last 5 years and did not cross time zones within the last month of the study.

Design outcomes

Primary

MeasureTime frameDescription
Postprandial Glucose Response12 weeksPostprandial Glucose response will be measure after lunch and dinner

Secondary

MeasureTime frameDescription
Postprandial Glucagon Response12 weeksPostprandial Glucagon response will be measure after lunch and dinner
Postprandial Free Fatty Acids Response12 weeksPostprandial Free Fatty Acids response will be measure after lunch and dinner
Postprandial Insulin Response12 weeksPostprandial Insulin response will be measure after lunch and dinner
Postprandial intact-GLP-1 Response12 weeksPostprandial intact-GLP-1 response will be measure after lunch and dinner

Countries

Israel, Venezuela

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026